Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Neoadjuvant EC-Paclitaxel in HER2-negative Inflammatory Breast Cancer
NCT03515798Phase 2Active, not recruiting
- Sponsor
- Institut Paoli-Calmettes
- Start
- Aug 2018
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in inflammatory breast cancer (IBC), sponsored by Institut Paoli-Calmettes. Started Aug 2018; status: active, not recruiting.
02
Drugs
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT03515798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03515798.